Ben Tran

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.

Hui-Ming Lin, Nicole Yeung, Jordan F Hastings, David R Croucher, Kevin Huynh, Thomas G Meikle, Natalie A Mellett, Edmond M Kwan, Ian D Davis, Ben Tran, Kate L Mahon, Alison Zhang, Martin R Stockler, Karen Briscoe, Gavin Marx, Patricia Bastick, Megan L Crumbaker, Anthony M Joshua, Arun A Azad, Peter J Meikle, et al.

Journal article  |  2021  |  Cancers (Basel)

Circulating lipids or cytokines are associated with prognosis in metastatic castration-resistant prostate cancer (mCRPC). This stu..

A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections

Paul Lloyd, Anne Hong, Marc A Furrer, Elaine WY Lee, Harveer S Dev, Maurice H Coret, James M Adshead, Peter Baldwin, Richard Knight, Jonathan Shamash, Constantine Alifrangis, Sara Stoneham, Danish Mazhar, Han Wong, Anne Warren, Ben Tran, Nathan Lawrentschuk, David E Neal, Benjamin C Thomas

Journal article  |  2021  |  WORLD JOURNAL OF UROLOGY

PURPOSE: To describe and compare differences in peri-operative outcomes of robot-assisted (RA-RPLND) and open (O-RPLND) retroperit..

Global Disparity in Access to Novel Therapeutics for Metastatic Prostate Cancer.

Angelyn Anton, Ben Tran

Journal article  |  2021  |  JCO Oncol Pract

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.

Edmond M Kwan, Lavinia Spain, Angelyn Anton, Chun L Gan, Linda Garrett, Deborah Chang, Elizabeth Liow, Caitlin Bennett, Tiantian Zheng, Jianjun Yu, Chao Dai, Pan Du, Shidong Jia, Heidi Fettke, Claire Abou-Seif, Gargi Kothari, Mark Shaw, Phillip Parente, Carmel Pezaro, Ben Tran, et al.

Journal article  |  2021  |  Eur Urol

BACKGROUND: Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest..

A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

Patrick Schoffski, Nicole Concin, Cristina Suarez, Vivek Subbiah, Yuichi Ando, Shiling Ruan, Joel P Wagner, Keith Mansfield, Xu Zhu, Shizuka Origuchi, Sarah DiDominick, Carl U Bialucha, Jason E Faris, Ben Tran

Journal article  |  2021  |  ONCOLOGY RESEARCH AND TREATMENT

PURPOSE: This first-in-human study (NCT02947152) evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of..

Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.

Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Marie C Semira, Peter Gibbs, Ben Tran, Carmel Pezaro

Journal article  |  2021  |  Eur J Cancer

INTRODUCTION: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related eve..

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.

M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, G Lo, B Tran, LA Wood, JR Gingerich, SA North, CJ Pezaro, JD Ruether, SS Sridhar, HML Kallio, DJ Khalaf, A Wong, et al.

Journal article  |  2021  |  Ann Oncol

BACKGROUND: Treatment of poor prognosis metastatic castration-resistant prostate cancer (mCRPC) includes taxane chemotherapy and a..

Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?

Amanda Pereira-Salgado, Edmond Michael Kwan, Ben Tran, Peter Gibbs, Johann De Bono, Maarten IJzerman

Journal article  |  2021  |  EUROPEAN UROLOGY FOCUS

CONTEXT: Optimal treatment sequencing of abiraterone and enzalutamide in chemotherapy-naïve metastatic castration-resistant prosta..

MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer

Patrick McCoy, Stefano Mangiola, Geoff Macintyre, Ryan Hutchinson, Ben Tran, Bernard Pope, Peter Georgeson, Matthew KH Hong, Natalie Kurganovs, Sebastian Lunke, Michael J Clarkson, Marek Cmero, Michael Kerger, Ryan Stuchbery, Ken Chow, Izhak Haviv, Andrew Ryan, Anthony J Costello, Niall M Corcoran, Christopher M Hovens

Journal article  |  2021  |  PROSTATE CANCER AND PROSTATIC DISEASES

BACKGROUND: Recent publications have shown patients with defects in the DNA mismatch repair (MMR) pathway driven by either MSH2 or..

Improving outcomes in germ cell cancers using miRNA

Ciara Conduit, Ben Tran

Journal article  |  2021  |  THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

Owing to advances in treatment paradigms across the last five decades, testicular cancer is now eminently curable. However, curren..